Small molecule · Inhibitor of influenza virus polymerase acidic (PA) endonuclease · developed by Sportpharm Llc
Baloxavir is an antiviral small molecule that inhibits the influenza virus polymerase acidic (PA) endonuclease, blocking viral RNA transcription. It is studied in influenza, including treatment of influenza-like illness and chemoprophylaxis in close contacts such as nursing home residents and staff.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Apr 24, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05012189 | Phase 4 | Influenza | Unknown | IMDX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
InfluenzaInfluenza -Like IllnessInfluenza, Human
Updated Oct 18, 2026.